Scientists have identified how prostate cancer transforms into a deadly treatment-resistant prostate cancer subtype called neuroendocrine prostate cancer (NEPC) following treatment with anti-androgen therapy. Their findings -- which include the metabolic rewiring and the epigenetic alteration that drives this switch -- reveal that an FDA-approved drug holds potential as a NEPC treatment.
from Latest Science News -- ScienceDaily https://ift.tt/2T6Deeg
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment